← Back to Search

PET Scans for Alzheimer's Disease (AcAc PET Trial)

N/A

Waitlist Available

Led By Suzanne Craft, PhD

Research Sponsored by Wake Forest University Health Sciences

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Mild cognitive impairment or subjective memory complaints

Ability to complete baseline assessments

Timeline

Screening 3 weeks

Treatment Varies

Follow Up change between baseline and four months

Awards & highlights

AcAc PET Trial Summary

This trial will study Alzheimer's Disease biomarkers and symptoms in patients following a ketogenic diet. Up to 60 patients will receive 3 PET scans over 18 weeks.

Who is the study for?

This trial is for individuals with mild cognitive impairment or memory concerns who are stable medically and can complete initial assessments. It's not suitable for those with a significant stroke history, sensory impairments, diabetes needing drugs, untreated thyroid or B12 issues, or those on certain medications like cholesterol-lowering drugs.Check my eligibility

What is being tested?

The study tests how [11C]Acetoacetate and [18F]Fluorodeoxyglucose distribute in the brain using PET scans. Participants from the BEAT-AD Study will have up to three scans over 18 weeks to see how these compounds behave in people at risk for Alzheimer's.See study design

What are the potential side effects?

As this is an imaging study involving PET scans, side effects may include discomfort from lying still during the scan and exposure to a small amount of radiation comparable to that received during some medical imaging procedures.

AcAc PET Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I experience memory problems or have been told I have mild cognitive issues.

Select...

I can complete initial health questionnaires and tests.

AcAc PET Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change between baseline and 4 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change between baseline and 4 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and change between baseline and 4 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Brain biodistribution of [11C]AcAc

Brain

AcAc PET Trial Design

3Treatment groups

Experimental Treatment

Group I: No risk of diseaseExperimental Treatment1 Intervention

Subjects with no identifiable risk of Alzheimer's Disease

Group II: Early Alzheimer's or Mild Cognitive ImpairmentExperimental Treatment1 Intervention

Subjects with early Alzheimer's Disease or Mild Cognitive Impairment (MCI)

Group III: AsymptomaticExperimental Treatment1 Intervention

Asymptomatic subjects with increased risk of Alzheimer's disease

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Wake Forest University Health SciencesLead Sponsor

1,240 Previous Clinical Trials

1,004,147 Total Patients Enrolled

Suzanne Craft, PhDPrincipal InvestigatorWake Forest University Health Sciences

16 Previous Clinical Trials

2,007 Total Patients Enrolled

Media Library

[11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan Clinical Trial Eligibility Overview. Trial Name: NCT03130036 — N/A

Mild Cognitive Impairment Research Study Groups: Asymptomatic, Early Alzheimer's or Mild Cognitive Impairment, No risk of disease

Mild Cognitive Impairment Clinical Trial 2023: [11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan Highlights & Side Effects. Trial Name: NCT03130036 — N/A

[11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan 2023 Treatment Timeline for Medical Study. Trial Name: NCT03130036 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants is the medical trial enrolling currently?

"Affirmative. According to the information uploaded on clinicaltrials.gov, this trial is currently enrolling; it was first posted on June 9th 2015 and last updated January 12th 2022. The research team requires 60 participants from a single site for the study."

Answered by AI

Does this experiment encompass elderly individuals?

"This medical trial has age criteria of those above the half-century mark and below 85 years old."

Answered by AI

Do I meet the requirements for participation in this research?

"Candidates who wish to be eligible for this trial must possess mild cognitive impairment (MCI) and fall into the age range of 50-85. 60 individuals will ultimately be accepted in total."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose in Subjects With Risk Factors for Alzheimer's Disease

2015. "Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose in Subjects With Risk Factors for Alzheimer's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03130036.

All > Alzheimers Disease High Point